BC Innovations | Apr 9, 2009
Distillery Therapeutics

This week in therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Lupus Kallikrein 1 (KLK1); KLK3 A study in human samples and in mice suggests that increasing kallikrein expression may...
BioCentury | Nov 17, 2008
Emerging Company Profile

Vantia: New irons in the fire

Vantia Therapeutics Ltd. spun out of Ferring Pharmaceuticals A/S with a portfolio of small molecules that includes a pair of vasopressin receptor modulators with disease-modifying potential. The company believes its lead program, a vasopressin 2...
Items per page:
1 - 2 of 2